Impact of the Mediterranean Diet on patients with CADASIL and Cerebral Amyloid Angiopathy
Effetto Della DIETa mEdiTerranea Sull'Incidenza di Ictus e Sul Decadimento Cognitivo in Pazienti Affetti da Cadasil e Angiopatia Cerebrale Amiloide
This study is testing whether following the Mediterranean Diet can help people with CADASIL and Cerebral Amyloid Angiopathy feel better and reduce their risk of strokes and cognitive decline.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 86 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT06933212 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the nutritional status and dietary habits of patients diagnosed with CADASIL and Cerebral Amyloid Angiopathy (CAA). It consists of two phases: the first phase evaluates adherence to the Mediterranean Diet and its relationship with stroke onset and cognitive decline, while the second phase involves an interventional dietary approach to further analyze the effects of the Mediterranean Diet. The study will measure various parameters, including lean and fat mass, basal metabolism, and total energy expenditure, to understand the potential benefits of dietary changes on these conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 18 and older with a confirmed diagnosis of CADASIL or probable CAA.
Not a fit: Patients without a diagnosis of CADASIL or CAA will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into how the Mediterranean Diet may help mitigate cognitive decline and stroke severity in patients with CADASIL and CAA.
How similar studies have performed: While the Mediterranean Diet has been studied for its general health benefits, this specific approach in CADASIL and CAA is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The study will include individuals of both sexes aged 18 years or older with a diagnosis of CADASIL (confirmed genetically by the presence of the NOTCH3 gene mutation) or possible/probable CAA (defined according to the Boston 2.0 criteria). All participants must provide informed consent for the use of demographic, clinical, and nutritional data for scientific purposes in an anonymous form Exclusion Criteria: * na
Where this trial is running
Milan
- Fondazione IRCCS Istituto Neurologico Carlo Besta — Milan, Italy (Recruiting)
Study contacts
- Study coordinator: Anna Bersano, MD
- Email: anna.bersano@istituto-besta.it
- Phone: 02 2394.3062
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.